Director of External Projects Appointed at Xenogesis
News Jan 31, 2015
Nottingham-based Clinical Research Organization (CRO) XenoGesis has appointed Graham Trevitt PhD as Director of External Projects.
Graham joins from Almac Discovery where he was Director of Medicinal Chemistry, responsible for medicinal chemistry strategy across all projects including integration of DMPK properties into the design and progression of compounds.
Commenting on the appointment, Managing Director, Richard Weaver said, “I am delighted to welcome Graham to the team. His appointment is of huge significance to us. Graham brings a wealth of experience, which will benefit the way we do things, and ultimately benefit the service we provide to our clients.”
“Graham will work closely with the XenoGesis team and clients to provide scientific leadership of client projects and consultative project management. He is also responsible for identifying ways in which we can improve the science behind the work that we carry out as well as how we can refine our prediction of how compounds will behave in man,” continued Richard.
“This is an exciting time for us in terms of growth. We are experiencing an increasing number of clients that are choosing to work with us because of our consultative approach to all our client projects, ensuring the most effective outcomes.”
Graham Trevitt added, “It is an exciting move for me and I share the clear vision Richard and his team have for XenoGesis. Being part of a fast-growing and dynamic CRO is a new challenge and one that I relish.”
XenoGesis is a specialist CRO focusing in preclinical drug metabolism and pharmacokinetics (DMPK), quantitative bioanalysis and expert interpretation. Founded by Richard Weaver in 2011 the business now employs 14 members of staff working at its premises in BioCity Nottingham.
Graham joins XenoGesis along new team members Sally Stinson and Liz Rendall who joined this month as Senior Research Scientists and Andrea O’Sullivan who joins as Office Administrator. Fay Davidson will be joining from Evotec in February as Research Scientist.
The cholesterol-lowering drugs called statins have demonstrated substantial benefits in reducing the risk of heart attacks and strokes caused by blood clots (ischemic strokes) in at-risk patients. Since statins are associated with a low risk of side effects, the benefits of taking them outweigh the risks, according to a scientific statement from the American Heart Association that reviewed multiple studies evaluating the safety and potential side effects of these drugs.READ MORE
18th International Conference on Pharmaceutics & Novel Drug Delivery Systems
May 27 - May 28, 2019
Global Experts Meeting on Frontiers in Biosimilars and Biologics Congress
Oct 24 - Oct 26, 2019